| 释义 |
1 ?珐博进 FG-4592最初由FibroGen(珐博进)研发，2006年授权给安斯泰来在亚洲、欧洲和南非地区的开发权。 2 ?血浆纤维蛋白原 抗凝和纤溶系统的指标:持续应用溶栓剂使机体处于高纤溶状态,可使血浆纤维蛋白原(fibrogen,Fg)含量降低,凝血酶时间(TT)延长,纤维蛋白(原)降解产物(FDPs)和D-二聚体(D-dimer,D... 3 ?纤维蛋白原 抗凝和纤溶系统的指标:持续应用溶栓剂使机体处于高纤溶状态,可使血浆纤维蛋白原(fibrogen,Fg)含量降低,凝血酶时间(TT)延长,纤维蛋白(原)降解产物(FDPs)和D-二聚体(D-dimer,D... 4 ?可使血浆纤维蛋白原 抗凝和纤溶系统的指标:持续应用溶栓剂使机体处于高纤溶状态,可使血浆纤维蛋白原(fibrogen,Fg)含量降低,凝血酶时间(TT)延长,纤维蛋白(原)降解产物(FDPs)和D-二聚体(D-dimer,D...
- 1.
In animal trials in 2001, Fibrogen's experimental drug cut collagen production by up to 70%. FORBES: Scar Wars - 2.
Small biotechs have picked up the slack, with Fibrogen and Intermune in the lead. FORBES: Scar Wars - 3.
Fibrogen researchers spent two years painstakingly screening 150 antibodies, and found 2 that hinder CTGF's ability to bind with cell receptors. FORBES: Scar Wars
|